<DOC>
	<DOC>NCT01771471</DOC>
	<brief_summary>This is a clinical study to collect safety and preliminary efficiency information on the use of NuQu chondrocytes (cartilage cells) delivered to the center of a lumbar spinal disc to treat low back pain.</brief_summary>
	<brief_title>A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo</brief_title>
	<detailed_description>This is a Phase II clinical study to collect additional safety data and preliminary efficiency of juvenile chondrocytes, delivered in fibrin carrier (NuQu®) to the nucleus of lumbar intervertebral discs for the treatment of discogenic pain. This to be accomplished through a double blinded, placebo-controlled study of clinically meaningful endpoints including validated, subject reported outcomes of pain and disability, health related quality of life and subject satisfaction with treatment.</detailed_description>
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>Subject is able to provide informed consent and must sign the Institutional Review Board approved Informed Consent Form; Is at least 21 years of age; Have central low back pain aggravated by movement and or postural changes (standing/sitting); Have had back pain for at least 6 months, and have failed conservative management One Grade III or IV (Pfirrmann Scale) degenerated lumbar disc; Current disc extrusion at any level in their lumbar spine; disc bulges or protrusions at any level in the lumbar spine resulting in nerve root compression; Severe disc narrowing (equal to or more than 50% loss of disc height at the targeted level); Type II or III Modic changes at any level; Type I Modic changes at any level other than the targeted level; Type I Modic changes at the treated level if maximum height of the changes is 25% or more of the vertebral body height; Osteoporotic compression fracture at any vertebral level; Lumbar Scheurmann's disease; Antero or retrolisthesis ≥ 3mm at any level; Currently experiencing chronic pain generating from any other source, which (in the judgment of the investigator) may interfere with the evaluation of back pain, and or disability; Infection at the planned treatment site, history of systemic or local infection, which (in the investigator's judgment) may compromise subject participation and/or safety; Currently diagnosed with immunedeficiency, which in the investigator's opinion may compromise subject participation and/or safety; Receiving any immunesuppressant therapies other than short term steroid preparations; BMI≥40; Diagnosed with any comorbid conditions including: abnormal bleeding, AIDS, diabetes, hepatic or renal disease, and cardiopulmonary disorders such as COPD, MI and CHF; active malignancy or history of malignancy, or diseases of bone metabolism, which in the investigator's opinion may compromise subject participation and/or safety; Has a history of alcoholism, medication or intravenous drug abuse, psychosis, is a prisoner, has a personality disorder(s), poor motivation, emotional or intellectual issues that would likely make the subject unreliable for the study, or 3 or more Waddell Signs of nonorganic Behavior or any combination of variables in the Investigator's judgment that should exclude a potential subject; Has pending litigation against a health care professional, except where required by the insurer as a condition of coverage, personal injury compensation or litigation claims; Has active or pending workers' compensation claims; Has contraindications for MRI.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>back pain</keyword>
	<keyword>intervertebral disc</keyword>
	<keyword>lumbar spine</keyword>
</DOC>